Your browser doesn't support javascript.
loading
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.
Restrepo, Marcos I; Babu, Bettina L; Reyes, Luis F; Chalmers, James D; Soni, Nilam J; Sibila, Oriol; Faverio, Paola; Cilloniz, Catia; Rodriguez-Cintron, William; Aliberti, Stefano.
Afiliação
  • Restrepo MI; Division of Pulmonary Diseases and Critical Care Medicine, University of Texas Health - San Antonio, San Antonio, TX, USA.
  • Babu BL; Division of Pulmonary Diseases and Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX, USA.
  • Reyes LF; Division of Pulmonary Diseases and Critical Care Medicine, University of Texas Health - San Antonio, San Antonio, TX, USA.
  • Chalmers JD; Division of Pulmonary Diseases and Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX, USA.
  • Soni NJ; Dept of Microbiology, Universidad de la Sabana, Chía, Colombia.
  • Sibila O; Dept of Critical Care Medicine, Clinica Universidad de La Sabana, Chía, Colombia.
  • Faverio P; School of Medicine, University of Dundee, Dundee, UK.
  • Cilloniz C; Division of Pulmonary Diseases and Critical Care Medicine, University of Texas Health - San Antonio, San Antonio, TX, USA.
  • Rodriguez-Cintron W; Division of Pulmonary Diseases and Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX, USA.
  • Aliberti S; Servei de Pneumologia, Departamento de Medicina, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Eur Respir J ; 52(2)2018 08.
Article em En | MEDLINE | ID: mdl-29976651
ABSTRACT
Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecção Hospitalar / Infecções Comunitárias Adquiridas / Pneumonia Bacteriana Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pseudomonas aeruginosa / Infecção Hospitalar / Infecções Comunitárias Adquiridas / Pneumonia Bacteriana Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article